Literature DB >> 30546642

Systemic and pulmonary artery aneurysms in incomplete Kawasaki disease.

Mario Briceno-Medina1, Michael Perez1, Benjamin R Waller1, Shyam Sathanandam1.   

Abstract

Kawasaki disease (KD) is a systemic vasculitis that can cause coronary artery aneurysms (CAA) in up to 25% if left untreated. Rarely, aneurysms of systemic arteries of all sizes have been reported to occur. The incidence of systemic artery aneurysms (SAA) with typical KD can be as high as 2.2%. Incomplete KD with SAA is not well described. We report a case of a 12-year-old boy with incomplete KD, giant CAA, diffuse SAA, and pulmonary artery aneurysms (PAA). The patient presented with fever, malaise, abdominal pain, maculopapular, rash and cervical lymphadenopathy. Echocardiogram showed multiple giant CAA. By angiography, diffuse ectasia and aneurysms of most medium-sized arteries throughout the body were noted including the lobar pulmonary artery branches. Incomplete KD was suspected. The patient was treated with intravenous gammaglobulin, methylprednisolone, and high-dose aspirin. Due to the systemic vasculitis, he also received cyclophosphamide. The patient's clinical symptoms improved. Anticoagulation with warfarin was maintained. The patient remains asymptomatic three years later but with progressive CAA and stable SAA. The PAA caused no symptoms and resolved after the acute phase. Incomplete KD can manifest with CAA and SAA. This is the first report of PAA associated with KD. Surveillance for PAA in KD must be considered. <Learning objective: A high level of clinical suspicion is required to diagnose KD in adolescent patients as it can manifest in an atypical fashion. Incomplete KD can manifest with giant CAA and SAA. Pulmonary artery aneurysms (PAA) have not been previously described in cases of KD. This is the first case report of atypical KD with PAA. Imaging of pulmonary arteries and its branches should be considered in patients with atypical KD with CAA and SAA.>.

Entities:  

Keywords:  Atypical Kawasaki disease; Giant coronary artery aneurysms; Systemic artery aneurysms

Year:  2016        PMID: 30546642      PMCID: PMC6280742          DOI: 10.1016/j.jccase.2016.02.003

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  9 in total

Review 1.  ABC of arterial and vascular disease: vasculitis.

Authors:  C O Savage; L Harper; P Cockwell; D Adu; A J Howie
Journal:  BMJ       Date:  2000-05-13

2.  Initial intravenous gammaglobulin treatment failure in Kawasaki disease.

Authors:  C A Wallace; J W French; S J Kahn; D D Sherry
Journal:  Pediatrics       Date:  2000-06       Impact factor: 7.124

Review 3.  Diagnosis and therapy of Kawasaki disease in children.

Authors:  A S Dajani; K A Taubert; M A Gerber; S T Shulman; P Ferrieri; M Freed; M Takahashi; F Z Bierman; A W Karchmer; W Wilson
Journal:  Circulation       Date:  1993-05       Impact factor: 29.690

4.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

5.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Circulation       Date:  2004-10-26       Impact factor: 29.690

6.  Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients.

Authors:  H Kato; T Sugimura; T Akagi; N Sato; K Hashino; Y Maeno; T Kazue; G Eto; R Yamakawa
Journal:  Circulation       Date:  1996-09-15       Impact factor: 29.690

Review 7.  Kawasaki syndrome.

Authors:  Jane C Burns; Mary P Glodé
Journal:  Lancet       Date:  2004 Aug 7-13       Impact factor: 79.321

8.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01

Review 9.  Epidemiology of Kawasaki disease in Asia, Europe, and the United States.

Authors:  Ritei Uehara; Ermias D Belay
Journal:  J Epidemiol       Date:  2012-02-04       Impact factor: 3.211

  9 in total
  6 in total

1.  Kawasaki disease does not affect coronaries alone: large vessels can be involved as well.

Authors:  Murugan Sudhakar; Manphool Singhal; Gummadi Anjani; Prabal Barman; Ningthoujam Anilbala; Pandiarajan Vignesh; Surjit Singh
Journal:  Clin Rheumatol       Date:  2022-03-08       Impact factor: 3.650

Review 2.  Kawasaki disease shock syndrome with acute respiratory distress syndrome in a child: a case report and literature review.

Authors:  Jingwei Liu; Chunfeng Yang; Zhen Zhang; Yumei Li
Journal:  BMC Pulm Med       Date:  2022-06-06       Impact factor: 3.320

3.  Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis.

Authors:  Yayoi Sato-Okabayashi; Kikuo Isoda; Beate Heissig; Tomoyasu Kadoguchi; Koji Akita; Kenichi Kitamura; Kazunori Shimada; Koichi Hattori; Hiroyuki Daida
Journal:  Int J Cardiol Heart Vasc       Date:  2020-05-10

4.  Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms.

Authors:  Olha Halyabar; Kevin G Friedman; Robert P Sundel; Annette L Baker; Margaret H Chang; Patrick W Gould; Jane W Newburger; Mary Beth F Son
Journal:  Pediatr Rheumatol Online J       Date:  2021-03-17       Impact factor: 3.054

5.  Lipocalin-2-induced proliferative endoplasmic reticulum stress participates in Kawasaki disease-related pulmonary arterial abnormalities.

Authors:  Zhaoling Shi; Yue Yin; Chen Li; Hui Ding; Nan Mu; Yishi Wang; Shanshan Jin; Heng Ma; Manling Liu; Jie Zhou
Journal:  Sci China Life Sci       Date:  2020-09-09       Impact factor: 6.038

6.  Neonatal Kawasaki disease with multiple arterial aneurysms: a case report.

Authors:  Qu-Ming Zhao; Xue-Cun Liang; Lin Wu; Fang Liu
Journal:  Pediatr Rheumatol Online J       Date:  2020-06-15       Impact factor: 3.054

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.